Literature DB >> 16806067

Expression and purification of the soluble isoform of human receptor for advanced glycation end products (sRAGE) from Pichia pastoris.

Thorsten Ostendorp1, Mirjam Weibel, Estelle Leclerc, Peter Kleinert, Peter M H Kroneck, Claus W Heizmann, Günter Fritz.   

Abstract

RAGE is a multi-ligand receptor involved in various human diseases including diabetes, cancer or Alzheimer's disease. Engagement of RAGE by its ligands triggers activation of key cellular signalling pathways such as the MAP kinase and NF-kappaB pathways. Whereas the main isoform of RAGE is a transmembrane receptor with both extra- and intracellular domains, a secreted soluble isoform (sRAGE), corresponding to the extracellular part only, has the ability to block RAGE signalling and suppress cellular activation. Administration of sRAGE to animal models of cancer or multiple sclerosis blocked successfully tumour growth and the course of the autoimmune disease. These findings demonstrate that sRAGE may have a potential as therapeutic. We present here a fast and simple purification protocol of sRAGE from the yeast Pichia pastoris. The identity of the protein was confirmed by mass spectrometry and Western blot. The protein was N-glycosylated and 95-98% pure as judged by SDS-PAGE.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16806067     DOI: 10.1016/j.bbrc.2006.04.077

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

1.  The G82S polymorphism promotes glycosylation of the receptor for advanced glycation end products (RAGE) at asparagine 81: comparison of wild-type rage with the G82S polymorphic variant.

Authors:  Sun Jin Park; Torsten Kleffmann; Paul A Hessian
Journal:  J Biol Chem       Date:  2011-04-21       Impact factor: 5.157

2.  Prothrombin is a binding partner of the human receptor of advanced glycation end products.

Authors:  Genny Degani; Alessandra Altomare; Stefania Digiovanni; Beatrice Arosio; Guenter Fritz; Angela Raucci; Giancarlo Aldini; Laura Popolo
Journal:  J Biol Chem       Date:  2020-07-14       Impact factor: 5.157

3.  Insights into the effects of N-glycosylation on the characteristics of the VC1 domain of the human receptor for advanced glycation end products (RAGE) secreted by Pichia pastoris.

Authors:  Genny Degani; Alberto Barbiroli; Paula Magnelli; Stefania Digiovanni; Alessandra Altomare; Giancarlo Aldini; Laura Popolo
Journal:  Glycoconj J       Date:  2019-01-05       Impact factor: 2.916

4.  Site-specific blockade of RAGE-Vd prevents amyloid-beta oligomer neurotoxicity.

Authors:  Emmanuel Sturchler; Arnaud Galichet; Mirjam Weibel; Estelle Leclerc; Claus W Heizmann
Journal:  J Neurosci       Date:  2008-05-14       Impact factor: 6.167

5.  Structural and functional insights into RAGE activation by multimeric S100B.

Authors:  Thorsten Ostendorp; Estelle Leclerc; Arnaud Galichet; Michael Koch; Nina Demling; Bernd Weigle; Claus W Heizmann; Peter M H Kroneck; Günter Fritz
Journal:  EMBO J       Date:  2007-07-26       Impact factor: 11.598

6.  Large scale isolation and purification of soluble RAGE from lung tissue.

Authors:  Judson M Englert; Lasse Ramsgaard; Zuzana Valnickova; Jan J Enghild; Tim D Oury
Journal:  Protein Expr Purif       Date:  2008-05-20       Impact factor: 1.650

7.  The extracellular region of the receptor for advanced glycation end products is composed of two independent structural units.

Authors:  Brian M Dattilo; Günter Fritz; Estelle Leclerc; Craig W Vander Kooi; Claus W Heizmann; Walter J Chazin
Journal:  Biochemistry       Date:  2007-05-18       Impact factor: 3.162

Review 8.  RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation.

Authors:  Louis J Sparvero; Denise Asafu-Adjei; Rui Kang; Daolin Tang; Neilay Amin; Jaehyun Im; Ronnye Rutledge; Brenda Lin; Andrew A Amoscato; Herbert J Zeh; Michael T Lotze
Journal:  J Transl Med       Date:  2009-03-17       Impact factor: 5.531

9.  RAGE mediates S100A4-induced cell motility via MAPK/ERK and hypoxia signaling and is a prognostic biomarker for human colorectal cancer metastasis.

Authors:  Mathias Dahlmann; Anna Okhrimenko; Patrick Marcinkowski; Marc Osterland; Pia Herrmann; Janice Smith; Claus W Heizmann; Peter M Schlag; Ulrike Stein
Journal:  Oncotarget       Date:  2014-05-30

10.  Advanced glycation end-products and their receptor-mediated roles: inflammation and oxidative stress.

Authors:  Parisa Younessi; Ali Yoonessi
Journal:  Iran J Med Sci       Date:  2011-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.